SBIR/STTR Research Award

VOLATILE MARKERS OF PULMONARY TUBERCULOSIS IN THE BREATH

Award identifier 5d2d0443aad101292ed559fe11fb26c4cdec17734014509af3040dee0228d7d4Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MENSSANA RESEARCH INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
N3KCXKLQNG35
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Background: Pulmonary tuberculosis (TB) is a growing public health problem, and detection is often costly and time-consuming. A breath test for volatile markers of Mycobacteria could provide a new test for the disease. An advanced new breath test routinely detects volatile organic compounds (VOCs) in breath in picomolar (10-12 mol/l) concentrations. M. tuberculosis manufactures volatile fatty acids and other volatile metabolites; detection of these VOCs in breath could provide an accurate, rapid, inexpensive and non-invasive new marker of infection in patients with active pulmonary TB. Experimental plan: In vitro study: Volatile metabolites in cultures of M. tuberculosis will be identified by gas chromatography and mass spectroscopy. Human study: In patients evaluated for suspected pulmonary TB, breath VOCs will be compared in those with and without disease. The sensitivity, specificity, and positive and negative predictive values of the breath test will be determined. Long term aims: a. Scientific: To determine the diagnostic accuracy of breath markers of M. tuberculosis. b. Technical: to develop a comparatively inexpensive miniaturized and rapid breath test suitable for clinical use and in less developed countries. c. Commercial: To obtain Food and Drug Administration (FDA) approval of the device and market it.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

19 SBIR/STTR records share this UEI (1993–2019). Reported award amounts total $10,351,169. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.